Acumen Pharmaceuticals Inc

NASDAQ ABOS

Download Data

Acumen Pharmaceuticals Inc Quick Ratio 3 year CAGR for the Trailing 12 Months (TTM) ending December 31, 2023

Acumen Pharmaceuticals Inc Quick Ratio 3 year CAGR is NA for the Trailing 12 Months (TTM) ending December 31, 2023. The quick ratio, also known as the acid-test ratio, measures a company's ability to meet its short-term obligations using its most liquid assets. It is calculated by dividing the current assets minus inventory by the current liabilities. This ratio provides insights into the company's liquidity position and its ability to pay off current liabilities without relying on inventory sales. A higher ratio suggests a stronger ability to meet short-term obligations with readily available assets. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Acumen Pharmaceuticals Inc Quick Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 30.28, a -49.28% change year over year.
  • Acumen Pharmaceuticals Inc Quick Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 59.70, a 1,336.91% change year over year.
  • Acumen Pharmaceuticals Inc Quick Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 4.16.
NASDAQ: ABOS

Acumen Pharmaceuticals Inc

CEO Mr. Daniel J. O'Connell M.B.A.
IPO Date July 1, 2021
Location United States
Headquarters 427 Park Street, Charlottesville, VA, United States, 22902
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email